| Literature DB >> 34702748 |
Sang Hum Lee1, Keon-Yeup Kim1, Jeong-Woo Lee2, So-Jeong Park2, Jin-Man Jung3,4.
Abstract
BACKGROUND: The exact pathophysiological mechanism of transient global amnesia (TGA) is unknown. It is debatable whether TGA is a risk factor for stroke. Therefore, here we investigated the possibility of TGA as a risk factor for stroke in a real-world setting using large-scale nationwide health claims data.Entities:
Keywords: stroke
Mesh:
Year: 2021 PMID: 34702748 PMCID: PMC9067272 DOI: 10.1136/svn-2021-001006
Source DB: PubMed Journal: Stroke Vasc Neurol ISSN: 2059-8696
Figure 1Flow chart for the selection of cases and controls based on a propensity score-matched cohort study of the National Health Insurance Service (NHIS) data. TGA, transient global amnesia.
Baseline characteristics of the TGA cases versus age-matched and sex-matched extraction group and absolute standardised differences after propensity score matching
| Clinical values | TGA case | Age-matched and sex-matched extraction group | Absolute standardised difference | |
| Before PS matching | After 1:2 PS matching | |||
| Age (years) | 60.5±12.6 | 60.7±12.4 | 0.018 | 0.032 |
| Female sex | 7067 (67.6) | 93 117 (66.3) | 0.027 | 0.013 |
| Stroke risk factors | ||||
| Hypertension | 5161 (49.3) | 53 017 (37.7) | 0.236* | 0.018 |
| DM | 3772 (36.1) | 29 933 (21.3) | 0.331* | 0.025 |
| Hyperlipidaemia | 5815 (55.6) | 32 462 (23.1) | 0.705* | 0.014 |
| Cardiac disease | ||||
| A-Fib | 263 (2.5) | 1727 (1.2) | 0.095 | 0.009 |
| MI | 262 (2.5) | 1536 (1.1) | 0.106* | 0.016 |
| Depressive d/o | 396 (3.8) | 1655 (1.2) | 0.168* | 0.051 |
| Anxiety d/o | 3858 (36.9) | 18 217 (13.0) | 0.575* | 0.045 |
| Seizure/epilepsy | 73 (0.7) | 528 (0.4) | 0.044 | 0.005 |
| Migraine | 1908 (18.2) | 8397 (6.0) | 0.382* | 0.069 |
| Antithrombotic user | 8383 (80.1) | 67 108 (47.8) | 0.716* | 0.009 |
Results are expressed as number (%) or mean±SD. Antithrombotics include antiplatelet agents and anticoagulants.
*Absolute standardised difference ≥0.1.
A-Fib, atrial fibrillation; DM, diabetes mellitus; d/o, disorder; MI, myocardial infarction; PS, propensity score; TGA, transient global amnesia.
Figure 2Standardised differences in variables included in the propensity score. Black lozenges indicate the entire study population (140 478 participants). Black dots indicate the propensity score-matched participants (20 493 participants). A-Fib, atrial fibrillation; DM, diabetes mellitus; d/o, disorder; MI, myocardial infarction.
Multivariable analysis of outcomes among TGA participants versus propensity score-matched control participants
| Variables | Crude HR (95% CI) | P value | Adjusted HR (95% CI)* | P value |
| Ischaemic stroke | 0.916 (0.846 to 0.992) | 0.032 | 1.194 (1.043 to 1.368) | 0.010 |
| Haemorrhagic stroke | ||||
| SAH | 0.993 (0.720 to 1.370) | 0.967 | 1.104 (0.665 to 1.832) | 0.702 |
| ICH | 0.943 (0.764 to 1.163) | 0.581 | 0.845 (0.606 to 1.177) | 0.319 |
| SDH | 1.684 (1.172 to 2.421) | 0.005 | 1.849 (0.997 to 3.430) | 0.051 |
| All-type stroke | 0.945 (0.878 to 1.018) | 0.140 | 1.197 (1.056 to 1.357) | 0.005 |
Total number of propensity score-matched participants, n=150 947 (10 461 patients with TGA and 140 486 control participants). Multivariable Cox regression analysis was used to examine the diagnoses of TGA and all-type stroke including ICH, SDH, SAH and ischaemic stroke.
*Adjusted for enrolment year.
ICH, intracerebral haemorrhage; SAH, subarachnoid haemorrhage; SDH, subdural haematoma; TGA, transient global amnesia.
Multivariable Cox regression analysis for ischaemic stroke and all types of stroke among TGA participants
| Clinical values | Ischaemic stroke | All-type stroke | ||||||
| Crude HR | P value | Adjusted HR* | P value | Crude HR | P value | Adjusted HR* | P value | |
| Hypertension | 0.381 (0.319 to 0.455) | <0.001 | 1.545 (1.266 to 1.885) | <0.001 | 0.415 (0.353 to 0.478) | <0.001 | 1.446 (1.206 to 1.732) | <0.001 |
| DM | 0.514 (0.438 to 0.603) | <0.001 | 1.321 (1.116 to 1.565) | 0.001 | 0.549 (0.473 to 0.637) | <0.001 | 1.252 (1.070 to 1.464) | 0.005 |
| Hyperlipidaemia | 0.757 (0.642 to 0.892) | <0.001 | 0.994 (0.790 to 1.128) | 0.527 | 0.756 (0.649 to 0.880) | <0.001 | 0.963 (0.817 to 1.135) | 0.654 |
| A-Fib | 0.370 (0.265 to 0.517) | <0.001 | 1.564 (1.106 to 2.213) | 0.011 | 0.376 (0.275 to 0.515) | <0.001 | 1.600 (1.156 to 2.215) | 0.004 |
| MI | 0.667 (0.435 to 1.022) | 0.063 | 0.881 (0.569 to 1.365) | 0.571 | 0.681 (0.456 to 1.018) | 0.061 | 0.890 (0.591 to 1.340) | 0.575 |
| Depressive d/o | 0.690 (0.480 to 0.990) | 0.044 | 1.234 (0.852 to 1.789) | 0.266 | 0.711 (0.505 to 1.000) | 0.050 | 1.206 (0.851 to 1.709) | 0.292 |
| Anxiety d/o | 0.822 (0.698 to 0.967) | 0.018 | 0.999 (0.843 to 1.184) | 0.991 | 0.805 (0.693 to 0.936) | 0.005 | 1.039 (0.887 to 1.216) | 0.639 |
| Seizure/epilepsy | 0.724 (0.329 to 1.595) | 0.423 | 1.433 (0.656 to 3.130) | 0.367 | 0.615 (0.306 to 1.236) | 0.172 | 1.687 (0.858 to 3.315) | 0.129 |
| Migraine | 0.861 (0.705 to 1.051) | 0.142 | 1.102 (0.899 to 1.352) | 0.350 | 0.900 (0.746 to 1.086) | 0.273 | 1.049 (0.866 to 1.270) | 0.628 |
| Antithrombotic user | 2.215 (1.703 to 2.881) | <0.001 | 1.048 (0.789 to 1.393) | 0.745 | 2.194 (1.721 to 2.796) | <0.001 | 1.108 (0.853 to 1.438) | 0.443 |
*Adjusted for age, sex and all other comorbidities.
A-fib, atrial fibrillation; DM, diabetes mellitus; d/o, disorder; MI, myocardial infarction; TGA, transient global amnesia.